Chenai Mathabire Rücker Sekai, Lissouba Pascale, Akinyi Milcah, Vicent Lubega Alex, Stewart Rosanna, Tamayo Antabak Natalia, Taremwa Mugisha Ivan, Ohler Liesbet, Macuácua Hélder, Atieno May, Muyindike Winnie, Turyahabwe Stavia, Odhiambo Okomo Gordon, Mahomed Couto Aleny, Musoke Mohammed, Bossard Claire, Hewison Catherine, Ndlovu Zibusiso, Huerga Helena
Epicentre Paris, France.
Médecins Sans Frontières Homa Bay, Kenya.
J Clin Tuberc Other Mycobact Dis. 2022 Apr 25;27:100316. doi: 10.1016/j.jctube.2022.100316. eCollection 2022 May.
The novel urine-based FujiLAM test identifies tuberculosis in HIV-positive patients but may be challenging to use at point-of-care (POC).
We assessed the feasibility and acceptability of using the FujiLAM test at point of care in outpatient settings.
We conducted a mixed methods study in four outpatient settings in Kenya, Mozambique, South Africa, and Uganda between November 2020 and September 2021. The test was performed at POC in existing clinic laboratories and consultation spaces. We performed direct observations in the four health facilities, individual questionnaires, proficiency testing evaluations, and individual interviews among healthcare workers performing the FujiLAM test (healthcare workers), and group discussions with programme managers.
Overall, 18/19 (95%) healthcare workers and 14/14 (100%) managers agreed to participate in the study. Most assessed healthcare workers, including lay health workers (10/11; 91%), met the minimum required theoretical knowledge and practical skill in performing the FujiLAM test. Most healthcare workers (17/18; 94%) found the FujiLAM test overall "" to perform. Some challenges were mentioned: many timed steps (5/18; 28%); ensuring correct incubation period (5/18; 28%); test result readability (4/18; 22%); and difficulties with cartridge buttons (3/18; 17%). Half of the healthcare workers regularly performing the test (4/7; 57%) found it "" to integrate into routine activities. Most healthcare workers and managers believed that any healthcare worker could perform the test after adequate training.
Implementing the FujiLAM test in outpatient POC settings is feasible and acceptable to healthcare workers and managers. This test can be performed in various clinic locations by any healthcare worker. The timed, multi-step test procedure is challenging and may affect the workload in resource-constrained health facilities.
新型尿液富士结核菌脂阿拉伯甘露聚糖(FujiLAM)检测可识别HIV阳性患者中的结核病,但在即时检测(POC)中使用可能具有挑战性。
我们评估了在门诊环境中即时使用富士LAM检测的可行性和可接受性。
2020年11月至2021年9月期间,我们在肯尼亚、莫桑比克、南非和乌干达的四个门诊机构开展了一项混合方法研究。该检测在现有诊所实验室和咨询空间的即时检测点进行。我们在这四个医疗机构进行了直接观察、个人问卷调查、能力验证评估,对进行富士LAM检测的医护人员(医护人员)进行了个人访谈,并与项目管理人员进行了小组讨论。
总体而言,18/19(95%)的医护人员和14/14(100%)的管理人员同意参与该研究。大多数接受评估的医护人员,包括非专业卫生工作者(10/11;91%),在进行富士LAM检测时达到了所需的最低理论知识和实践技能要求。大多数医护人员(17/18;94%)认为富士LAM检测总体上“易于操作”。提到了一些挑战:许多计时步骤(5/18;28%);确保正确的孵育期(5/18;28%);检测结果的可读性(4/18;22%);以及试剂盒按钮操作困难(3/18;17%)。一半定期进行该检测的医护人员(4/7;57%)发现它“易于”融入日常活动。大多数医护人员和管理人员认为,经过充分培训后,任何医护人员都可以进行该检测。
在门诊即时检测环境中实施富士LAM检测对医护人员和管理人员来说是可行且可接受的。任何医护人员都可以在不同的诊所地点进行该检测。计时的多步骤检测程序具有挑战性,可能会影响资源有限的医疗机构的工作量。